Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TB 100 - Therabest

Next Previous
X
Search
Drug Profile

TB 100 - Therabest

Alternative Names: RY 110; TB-100-Therabest

Latest Information Update: 18 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reyon Pharmaceutical; Therabest Korea
  • Developer Therabest Korea
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours; Triple negative breast cancer

Most Recent Events

  • 11 Apr 2023 Therbest Korea signs a joint development agreement with Reyon Pharmaceutical for the development of TB 100 (Reyon Pharmaceuticals pipeline, July 2023)
  • 13 Dec 2022 Therabest Korea and Glycotope enters into an agreement for the clinical development of TB 100 in Triple-negative breast cancer (Combination therapy)
  • 13 Dec 2022 Preclinical trials in Solid tumours in South Korea (Parenteral), prior to December 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top